Osteomyelitis (Refractory)

HBOT has been approved as an adjunctive treatment of Osteomyelitis (bone infection), especially in cases where it is refractory or non-responsive. By improving circulation, supersaturating tissue with plasma oxygen, enhancing ability to fight infection, bactericidal to bugs that cannot handle higher oxygen levels, supporting overall immune function, and promoting all stages of bone and wound healing, HBOT can be an excellent treatment to aid in resistant infections of osteomyelitis.